Core Viewpoint - Aikang Group is facing controversy over alleged "fake health checkups" following a case where a client, Ms. Zhang, was diagnosed with kidney cancer after ten years of health checkups without prior warnings from the company [1][8]. Group 1: Company Response - Aikang Group held a media briefing to clarify that there were no flaws in Ms. Zhang's kidney examinations and that the claims of "fake health checkups" are unfounded [1][2]. - The company has initiated legal action against Ms. Zhang for spreading false information, which has been accepted by the court [1][6]. Group 2: Health Checkup Process - Aikang Group's CEO, Zhang Ligang, emphasized that health checkups are not equivalent to medical diagnoses and are designed to help identify potential health issues, requiring follow-up with specialists for further diagnosis [3]. - The health checkup report for Ms. Zhang indicated potential issues, including a left kidney hamartoma and a calcification in the right kidney, with recommendations for further examinations [3][5]. Group 3: Quality Control and Data Management - Aikang Group's Vice President, Wang Zhaohui, presented quality control data for cancer marker tests conducted on Ms. Zhang, asserting that the data is traceable and that there are no "fake health checkups" [4]. - The company clarified that it cannot retain blood samples for ten years due to industry standards, which typically allow for a preservation period of 1-7 days [5]. Group 4: Ms. Zhang's Claims - Ms. Zhang reported that her health checkup results over the years indicated no significant abnormalities until a later diagnosis of kidney cancer, raising concerns about potential misdiagnosis or oversight by Aikang Group [8][9]. - Following her diagnosis, Ms. Zhang has sought complaints with various health authorities, demanding accountability from Aikang Group [9].

Core Viewpoint - The controversy surrounding Aikang Guobin involves allegations of "fake health check-ups" after a lawyer, Zhang Xiaoling, was diagnosed with cancer despite years of normal test results from the company [1][2]. Group 1: Allegations and Responses - Zhang Xiaoling claims that Aikang Guobin's health checks failed to detect her cancer risk over a decade, leading to a late-stage diagnosis [1][2]. - Aikang Guobin has conducted internal and external evaluations, asserting that there were no misdiagnoses or false checks, and has initiated legal action against Zhang for defamation [2][6]. - The company emphasizes that health checks are not equivalent to medical diagnoses and are intended to identify potential health issues for further investigation by specialists [3]. Group 2: Medical Insights and Procedures - Aikang Guobin's medical professionals clarified that the 2023 ultrasound report indicated potential issues that warranted further examination, contradicting Zhang's claims [3][5]. - The company highlighted that cancer markers like carcinoembryonic antigen (CEA) are not reliable for early detection of kidney cancer, as imaging techniques are the primary diagnostic tools [5]. - Aikang Guobin maintains that it follows industry standards regarding the retention of blood samples, which typically last only 1-7 days, making it impossible to keep samples from the past decade [4]. Group 3: Impact on the Industry - The allegations have raised concerns about public trust in private health check-up centers and the broader healthcare industry in China, affecting the reputation of Aikang Guobin and its employees [6]. - The company asserts that the claims have harmed its reputation and the trust of its approximately 8 million annual clients [6].